Skip to podcast content

GLP-1 Hub Podcast

Employer Dropping GLP-1 Coverage? Questions to Ask Before Your Next Refill

By the GLP-1 Hub editorial teamArticle published With Jay BregmanEpisode released August 13, 2026

Jay Bregman explains employer contributions and the economics behind access, with practical questions for comparing benefits and planning continuity of care.

Listen to this episode

The GLP-1 Hub Podcast

Open episode on Buzzsprout

If your employer is changing GLP-1 coverage, start by finding out exactly what is changing and when. A denied prescription, a new authorization requirement and the removal of a benefit are different problems. The most useful next step is a written explanation of your own plan, followed by a conversation with your prescriber before access is interrupted.

Jay Bregman, founder and CEO of Andel, discusses why employers struggle with the cost of long-term medicines in his interview with Ana Reisdorf. He also describes a different approach: an employer contributes a set amount toward access through a direct purchasing arrangement. Because he sells a service in this market, his perspective is a business participant’s explanation, not an independent assessment of every coverage option.

Why an effective medicine can still become harder to access

Bregman distinguishes a medicine’s potential long-term value from the expense a payer sees today. An employer may face a large current pharmacy bill while benefits such as better health over decades accrue later, possibly after the employee has changed jobs. That is his explanation for a financing tension, not evidence that every employer makes the same decision.

He also describes the time and administrative work involved in authorizations and denials. Reisdorf gives a concrete example from her own experience: receiving an approval letter and denial letters on the same day. For a patient, that confusion can be as urgent as the headline price because it leaves the next refill uncertain.

The distinction to keep in mind is that clinical appropriateness and payment approval are separate decisions. A coverage change does not by itself explain what treatment should replace the medicine, or whether a clinically successful treatment should end.

Find out which access problem you actually have

Ask the benefits administrator or plan for the current terms that apply to your product and indication. You want to know whether the medicine is excluded, covered with conditions, awaiting information or denied under a particular criterion. If a change is scheduled, ask for its effective date and what it means for existing prescriptions.

Useful questions include:

  • Is this a change to the benefit itself or a decision on my individual request?
  • Which written provision or criterion was used?
  • Is continuation of treatment evaluated differently from starting treatment?
  • What is the appeal or exception process, and what deadline applies?
  • Who can confirm the answer in writing?

CMS explains that plan documents describe how to appeal a coverage dispute and that external review may be available in qualifying situations. This is not a guarantee that an appeal will reverse a benefit exclusion. Follow the procedure that applies to your plan and seek appropriate benefits assistance when the explanation is unclear.

A fixed employer contribution is not full coverage

Bregman’s model lets an employer choose a predictable contribution rather than pay an open-ended amount for each eligible employee. The employee pays the remaining cost. That could provide help where a traditional benefit is unavailable, but the size of the contribution is only part of the comparison.

Consider an illustrative example, not a quoted offer: if the medicine and required services total $400 a month and an employer contributes $150, the remaining expense is $250. If a separate membership or clinical fee applies, it belongs in that calculation too. A larger advertised contribution is not necessarily a better deal if the underlying total is higher.

Ask whether participation changes your usual clinical care, which pharmacy fills the prescription, whether prices vary by dose, and what happens when you leave the job. Also ask how the arrangement relates to your insurance deductible and other benefits rather than assuming that a direct payment works like an insurance claim.

Compare a workable year, not just the first month

Bregman encourages listeners to look at current manufacturer options as well as employer benefits. The important word is current: eligibility, products, prices and terms can change. A price mentioned in the interview is not a standing offer, and a future medicine is not a continuity plan for next month.

Request the ongoing total after any introductory period, the renewal conditions and the cost of necessary visits or monitoring. A lower drug price can be less useful if the service does not provide the clinical support you need. Avoid changing products or stretching a dosing schedule solely to make a quoted price fit.

For the clinical side of provider selection, our conversation with Sabina Hemmi examines what to ask about accessible, ongoing GLP-1 care.

Plan the handoff before the supply runs out

Tell your prescriber when you expect coverage to change and how much prescribed medication you have remaining. Ask what information the office can provide for a review, what alternatives are medically appropriate, and how to handle any interruption. A safe plan depends on the medicine and why you take it.

The aim is not to solve the whole financing system yourself. It is to turn a vague threat of lost access into a dated, specific set of facts: the benefit terms, the real ongoing cost and the care plan for your next refill. Those facts make both a benefits conversation and a clinical conversation more productive.

The complete conversation

Prefer to read?

Explore the full episode transcript, with speaker labels and the original discussion.

Read the transcript